$0.41
5.32% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US09077B1044
Symbol
BCAB
Sector
Industry

BioAtla Inc Stock price

$0.41
-0.03 7.76% 1M
-1.04 72.03% 6M
-0.19 31.41% YTD
-1.16 74.17% 1Y
-17.59 97.75% 5Y
-17.59 97.75% 10Y
-17.59 97.75% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.02 5.32%
ISIN
US09077B1044
Symbol
BCAB
Sector
Industry

Key metrics

Market capitalization $25.02m
Enterprise Value $-7.34m
EV/FCF (TTM) EV/FCF 0.13
P/B ratio (TTM) P/B ratio 45.56
Free Cash Flow (TTM) Free Cash Flow $-57.40m
Cash position $32.36m
P/E forward negative
Short interest 8.14%

Is BioAtla Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

BioAtla Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a BioAtla Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a BioAtla Inc forecast:

Buy
67%
Hold
33%

Financial data from BioAtla Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
16% 16%
199%
- Research and Development Expense 63 63
39% 39%
574%
-73 -73
43% 43%
-664%
- Depreciation and Amortization 0.93 0.93
24% 24%
8%
EBIT (Operating Income) EBIT -74 -74
43% 43%
-672%
Net Profit -70 -70
43% 43%
-634%

In millions USD.

Don't miss a Thing! We will send you all news about BioAtla Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioAtla Inc Stock News

Neutral
GlobeNewsWire
12 days ago
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA) SAN DIEGO,...
Neutral
Seeking Alpha
about one month ago
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Jeet Mukherjee – BTIG Reni Benj...
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2025 and provided highlights on its clinical programs.
More BioAtla Inc News

Company Profile

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Jay Short
Employees 65
Founded 2007
Website www.bioatla.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today